Search our Database of Scientific Publications and Authors

I’m looking for a
    Are there risk factors for scleroderma-related calcinosis?
    • Authors:
    • Sneha Pai
      Englewood Hospital and Medical Center
      Vivien Hsu
      Rutgers-Robert Wood Johnson Medical School
    Mod Rheumatol 2017 Jul 19:1-5. Epub 2017 Jul 19.
    b Department of Medicine, Division of Rheumatology and Connective Tissue Research , Rutgers-Robert Wood Johnson Medical School , New Brunswick , NJ , USA.
    Objectives: Pathogenesis and risk factors of scleroderma associated calcinosis is poorly understood and there is no effective treatment. This study was performed to better understand the prevalence and clinical features associated with calcinosis in a cohort of SSc outpatients.

    Methods: In this cross-sectional study, we compared clinical characteristics of SSc patients with (SSc-calcinosis) and without calcinosis (SSc-control) seen in the outpatient Rutgers-RWJ Scleroderma Program between 2012 and 2015. Our analysis included clinical characteristics, comorbidities (i.e. osteoporosis), autoantibodies and imaging results. We performed univariable and multivariable regression analyses to determine common factors associated with calcinosis.

    Results: There were 215 SSc patients, including 65 SSc-calcinosis (81.5% females) and 150 SSc-without calcinosis (controls, 77% females). SSc-calcinosis patients were older (p = .026) with significantly longer disease duration (20 ± 10.5 years versus 12 ± 8 years, p < .0001). Limited cutaneous scleroderma was more common (54%) in the calcinosis group. Longer disease duration from non-Raynaud symptoms (OR 3.77; 95%CI 1.26, 11.27) and osteoporosis (OR 3.43; 95%CI 1.15, 10.36) remained independently associated with calcinosis.

    Conclusions: Calcinosis was common in both limited and diffuse systemic sclerosis; both longer disease duration and osteoporosis were independently associated with calcinosis. Prospective studies are needed to confirm our findings.

    Similar Publications

    Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study.
    Semin Arthritis Rheum 2016 Dec 2;46(3):344-349. Epub 2016 Jun 2.
    Department of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203 MC 5755, Palo Alto, CA 94304. Electronic address:
    Objectives: We sought to identify the clinical factors associated with calcinosis in an international multicenter collaborative effort with the Scleroderma Clinical Trials Consortium (SCTC).

    Methods: This is a retrospective cohort study of 5218 patients with systemic sclerosis (SSc). Logistic regression was used to obtain odds ratios (OR) relating calcinosis to various clinical features in multivariate analyses. Read More
    History of surgical debridement, anticentromere antibody, and disease duration are associated with calcinosis in patients with systemic sclerosis.
    Scand J Rheumatol 2016 8;45(2):114-7. Epub 2015 Oct 8.
    a Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust , The University of Manchester, Manchester Academic Health Science Centre , Manchester , UK.
    Objectives: Systemic sclerosis (SSc)-related calcinosis is often painful and disabling. Our aim was to examine its clinical and serological associates, and whether it is possible to build a model to predict the presence of calcinosis.

    Method: This was a retrospective cross-sectional study. Read More
    X-ray diffraction analysis of spontaneously draining calcinosis in scleroderma patients.
    Scand J Rheumatol 2017 Mar 28;46(2):118-121. Epub 2016 Sep 28.
    b Department of Chemistry and Chemical Biology , Rutgers, The State University of New Jersey, Wright-Rieman Laboratories , Piscataway , NJ , USA.
    Objectives: Calcium hydroxyapatite (HA) is reported to be the major constituent of soft tissue calcinosis in patients with scleroderma (systemic sclerosis, SSc). Mechanical stress and local tissue hypoxia are thought to be important in the pathogenesis of SSc calcinosis. We sought to analyse spontaneously draining material from calcinosis sites in SSc patients using X-ray diffraction (XRD). Read More
    Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.
    Arthritis Res Ther 2011 22;13(6):R211. Epub 2011 Dec 22.
    The University of Melbourne, Department of Medicine, St, Vincent's Hospital Melbourne, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia.
    Introduction: The prevalence of antibodies to RNA polymerase III (anti-RNAP) differs among systemic sclerosis (SSc) cohorts worldwide. Previously reported associations of anti-RNAP include diffuse cutaneous disease, tendon friction rubs and renal crisis, with recent reports suggesting a close temporal association between malignancy and SSc disease onset among patients with anti-RNAP.

    Methods: Patients with SSc were tested for the presence of anti-RNAP at recruitment into the Australian Scleroderma Cohort Study. Read More